{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:54:52Z","timestamp":1776318892327,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,2,16]],"date-time":"2005-02-16T00:00:00Z","timestamp":1108512000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s00198-004-1799-7","type":"journal-article","created":{"date-parts":[[2005,2,15]],"date-time":"2005-02-15T10:11:33Z","timestamp":1108462293000},"page":"707-711","source":"Crossref","is-referenced-by-count":65,"title":["Fracture risk in patients with prostate cancer on androgen deprivation therapy"],"prefix":"10.1007","volume":"16","author":[{"given":"Ana M.","family":"L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda A.","family":"Pena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Val","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Riancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,2,16]]},"reference":[{"key":"1799_CR1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.eursup.2003.12.002","volume":"3","author":"Bono","year":"2004","unstructured":"Bono AV (2004) Overview of current treatment strategies in prostate cancer. Eur Urol Suppl 3:2\u20137","journal-title":"Eur Urol Suppl"},{"key":"1799_CR2","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1097\/01.ju.0000059281.67667.97","volume":"169","author":"Melton","year":"2003","unstructured":"Melton LJ III, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H (2003) Fracture risk following bilateral orchiectomy. J Urol 169:1747\u20131750","journal-title":"J Urol"},{"key":"1799_CR3","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0022-5347(05)65060-4","volume":"167","author":"Ross","year":"2002","unstructured":"Ross RW, Small EJ (2002) Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 167:1952\u20131956","journal-title":"J Urol"},{"key":"1799_CR4","first-page":"288","volume":"76","author":"Goldray","year":"1993","unstructured":"Goldray D, Weisman Y, Jaccard N, Merdler C, Chen J, Matzkin H (1993) Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (d-Trp-GnRH). J Clin Endocrinol Metab 76:288\u2013290","journal-title":"J Clin Endocrinol Metab"},{"key":"1799_CR5","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","volume":"167","author":"Berruti","year":"2002","unstructured":"Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, Reimondo G, Mari M, Ardissone P, De Luca S, Fasolis G, Fontana D, Rossetti SR, Angeli A (2002) Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167:2361\u20132367","journal-title":"J Urol"},{"key":"1799_CR6","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","volume":"87","author":"Mittan","year":"2002","unstructured":"Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87:3656\u20133661","journal-title":"J Clin Endocrinol Metab"},{"key":"1799_CR7","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.0.CO;2-Z","volume":"83","author":"Diamond","year":"1998","unstructured":"Diamond T, Campbell J, Bryant C, Lynch WB (1998) The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83:1561\u20131566","journal-title":"Cancer"},{"key":"1799_CR8","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0022-5347(05)65661-3","volume":"166","author":"Oefelein","year":"2001","unstructured":"Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M (2001) Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166:1724\u20131728","journal-title":"J Urol"},{"key":"1799_CR9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2003-0003","volume":"25","author":"Vandevyver","year":"2004","unstructured":"Vandevyver C, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C (2004) Androgens and bone. Endocr Rev 25:389\u2013425","journal-title":"Endocr Rev"},{"key":"1799_CR10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1172\/JCI10942","volume":"106","author":"Falahati-Nini","year":"2000","unstructured":"Falahati-Nini A, Riggs BL, Atkinson EJ, O\u2019Fallon M, Estell R, Khosla S (2000) Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1533\u20131560","journal-title":"J Clin Invest"},{"key":"1799_CR11","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1172\/JCI119701","volume":"100","author":"Slemenda","year":"1997","unstructured":"Slemenda CW, Longcope C, Zhou L, Hui SH, Peacock M, Johnston CC (1997) Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 100:1755\u20131759","journal-title":"J Clin Invest"},{"key":"1799_CR12","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1210\/jc.2003-030736","volume":"88","author":"Gennari","year":"2003","unstructured":"Gennari L, Merlotti D, Martini G, Gonnelli S, Franci B, Campagna S, Lucani B, Dal Canto N, Valenti R, Gennari C, Nuti R (2003) Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 88:5333.","journal-title":"J Clin Endocrinol Metab"},{"key":"1799_CR13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bone.2004.02.013","volume":"35","author":"Zarrabeitia","year":"2004","unstructured":"Zarrabeitia A, Zarrabeitia MT, Valero C, Gonz\u00e1lez-Mac\u00edas J, Riancho JA (2004) Age-related influence of common aromatase gene polymorphisms on bone mass of healthy men. Bone 35:243\u2013248","journal-title":"Bone"},{"key":"1799_CR14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0022-5347(01)67098-8","volume":"154","author":"McGrath","year":"1995","unstructured":"McGrath SA, Diamond T (1995) Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. J Urol 154:535\u2013536","journal-title":"J Urol"},{"key":"1799_CR15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF00295959","volume":"54","author":"Collinson","year":"1994","unstructured":"Collinson MP, Tyrrel CJ, Hutton C (1994) Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate. Calcif Tissue Int 54:327\u2013328","journal-title":"Calcif Tissue Int"},{"key":"1799_CR16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/sj.bjc.6601191","volume":"89","author":"Dhillon","year":"2003","unstructured":"Dhillon T, Waxman J (2003) Osteoporosis and prostate cancer. Br J Cancer 89:779\u2013780","journal-title":"Br J Cancer"},{"key":"1799_CR17","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.20056","volume":"100","author":"Diamond","year":"2004","unstructured":"Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR (2004) Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100:892\u2013899","journal-title":"Cancer"},{"key":"1799_CR18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","volume":"57","author":"Kiratli","year":"2001","unstructured":"Kiratli BJ, Srinivas S, Perkash I, Terris MK (2001) Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57:127\u2013132","journal-title":"Urology"},{"key":"1799_CR19","first-page":"2787","volume":"86","author":"Stoch","year":"2001","unstructured":"Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, Greenspan SL (2001) Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86:2787\u20132791","journal-title":"J Clin Endocrinol Metab"},{"key":"1799_CR20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3","volume":"79","author":"Townsend","year":"1997","unstructured":"Townsend MF, Sanders WH, Northway RO, Graham SD Jr (1997) Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79:545\u2013550","journal-title":"Cancer"},{"key":"1799_CR21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1464-410X.2000.00774.x","volume":"86","author":"Hatano","year":"2000","unstructured":"Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K (2000) Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 86:449\u2013452","journal-title":"BJU Int"},{"key":"1799_CR22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s001980200074","volume":"13","author":"Ismail","year":"2002","unstructured":"Ismail AA, Pye SR, Cockerill WC, Lunt M, Silman AJ, Reeve J, et al (2002) Incidence of limb fracture across Europe: results from the European prospective osteoporosis study (EPOS). Osteoporos Int 13:565\u2013571","journal-title":"Osteoporos Int"},{"key":"1799_CR23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0889-8529(05)70009-8","volume":"27","author":"Orwoll","year":"1998","unstructured":"Orwoll ES (1998) Osteoporosis in men. Endocr Metab Clin N Am 27:349\u2013367","journal-title":"Endocr Metab Clin N Am"},{"key":"1799_CR24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s001980050222","volume":"10","author":"Sanders","year":"1999","unstructured":"Sanders KM, Seeman E, Ugoni AM, Pasco JA, Martin TJ, Skoric B, Nicholson GC, Kotowicz MA (1999) Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporos Int 10:240\u2013247","journal-title":"Osteoporos Int"},{"key":"1799_CR25","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","volume":"91","author":"Smith","year":"2001","unstructured":"Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS (2001) Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 91:2238\u20132245","journal-title":"Cancer"},{"key":"1799_CR26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(99)00301-5","volume":"54","author":"Wei","year":"1999","unstructured":"Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ, Cooney KA (1999) Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54:607\u2013611","journal-title":"Urology"},{"key":"1799_CR27","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008\u20132012","journal-title":"J Urol"},{"key":"1799_CR28","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","volume":"345","author":"Smith","year":"2001","unstructured":"Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948\u2013955","journal-title":"N Engl J Med"},{"key":"1799_CR29","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","volume":"92","author":"Diamond","year":"2001","unstructured":"Diamond TH, Winters J, Smith A, De Souza P, Kersley JH, Lynch WJ, Bryant C (2001) The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 92:1444\u20131450","journal-title":"Cancer"},{"key":"1799_CR30","first-page":"511","volume":"86","author":"Leder","year":"2001","unstructured":"Leder BZ, Smith MR, Fallon MA, Lee ML, Finkelstein JS (2001) Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 86:511\u2013516","journal-title":"J Clin Endocrinol Metab"},{"key":"1799_CR31","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","volume":"89","author":"Smith","year":"2004","unstructured":"Smith MR, Fallon MA, Lee H, Finkelstein JS (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841\u20133846","journal-title":"J Clin Endocrinol Metab"},{"key":"1799_CR32","first-page":"2869","volume":"86","author":"Taxel","year":"2001","unstructured":"Taxel P, Kennedy DG, Fall PM, Willard AK, Clive JM, Raisz LG (2001) The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J Clin Endocrinol Metab 86:2869\u20132874","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-004-1799-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-004-1799-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-004-1799-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:03:52Z","timestamp":1558609432000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-004-1799-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,16]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["1799"],"URL":"https:\/\/doi.org\/10.1007\/s00198-004-1799-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,16]]}}}